Baseline (year 2 original cohort and year 5 minority cohort) C-reactive protein (CRP) was measured by a colorimetric competitive ELISA developed in our laboratory (Macy, et al, 1997). Biotinylated CRP competes with CRP in the sample for the coated antibody. Detection is via the enzyme horseradish peroxidase conjugated in an avidin-biotin complex followed by the color reagent substrate, orthophenylene diamine. Standardization is done using the WHO CRP reference standard. The analytical coefficient of variation for this assay was 5.1%.

- Macy E, Hayes T, Tracy R (1997) Variability in the measurement of C-reactive protein in healthy subjects: implication for reference interval and epidemiological applications. Clin Chem 43:52-58.

Year 5 (year 5 original cohort and year 5 minority cohort) and year 9 C-reactive protein (CRP) was measured using the BNII nephelometer from Dade Behring (N High Sensitivity CRP: Dade Behring Inc., Deerfield, IL). This instrument utilizes a particle enhanced immunonepholometric assay. Polystyrene particles are coated with monoclonal antibodies to CRP, which, in the presence of antigen (CRP) agglutinate to cause an increase in the intensity of scattered light. The analytical coefficient of variation for this assay was 5.0%.

In order to use the data longitudinally, CRP levels which had been measured by the ELISA in the minority cohort at their year 5 baseline visit were re-measured using the automated BNII assay. 641 participants had duplicate measures available for comparison. An adjustment formula was calculated (CRP_{BNII} = exp(ln(CRP_{ELISA} + 0.2781).

02 |
03 |
04 |
05 |
06 |
07 |
08 |
09 |
10 |
11 |
18 |
|||||

Analyte |
Full |
C/C |
X-See |
C/C-2 |
Original |
Black only |
|||||||||

Lipids: |
|||||||||||||||

Cholesterol^{1} |
X | 1/4FC | 1/4FC | X | X | X | X | 1/4FC | X | X | X | X | |||

LDL-C | X | X | X | X | |||||||||||

HDL-C^{1} |
X | X | X | X | |||||||||||

Triglyceride^{1} |
X | X | X | X | |||||||||||

Lp(a)^{1} |
X | ||||||||||||||

Plasma Oxysterol | 1/60MS ^{36} |
||||||||||||||

fatty acids^{1} |
X | X^{17} |
|||||||||||||

Coag Factors: |
|||||||||||||||

Procoagulants: | |||||||||||||||

Fibrinogen^{1} |
X | X | X | ||||||||||||

Prothrombin^{2} |
X^{10} |
X | 1/3FC | ||||||||||||

Factor VIIc^{1} |
X | X | X | ||||||||||||

Factor VIIIc^{1,10} |
X,L | ||||||||||||||

Factor VIIag^{2} |
X | ||||||||||||||

Factor VIIa^{2} |
X | ||||||||||||||

Factor IX^{2} |
X | ||||||||||||||

Factor X^{2} |
X | ||||||||||||||

Factor XI | X^{35} |
X^{35} |
|||||||||||||

Gamma Prime Fibrinogen | X^{35} |
X^{35} |
|||||||||||||

Fragment 1.2^{2,10} |
X^{10} |
X | 1/10FC | 1/3FC | |||||||||||

Fibrinopeptide A^{2} |
X | ||||||||||||||

Factor XIa- a _{1}AT Complex^{2} |
X | ||||||||||||||

Inhibitors: | |||||||||||||||

Protein C^{2,10} |
X | 1/10FC | |||||||||||||

Protein S (F+B)^{2} |
X | ||||||||||||||

Antithrombin III^{2,10} |
X^{10} |
X | 1/10FC | ||||||||||||

Tissue Factor Pathway Inhib.^{2} |
X | ||||||||||||||

Thrombin activated fibrinolysis inhibitor (TAFI)^{13} |
X | ||||||||||||||

EPCR^{5} |
X | subset | |||||||||||||

Fibrinolysis: | |||||||||||||||

t-PA^{2} |
X | 1/3FC | |||||||||||||

PAI-1^{2} |
X^{10} |
X | 1/3FC | ||||||||||||

tPA/PAI-1 Complex^{2} |
X | ||||||||||||||

Plasminogen^{2} |
X | ||||||||||||||

Plasmin/Antiplasmin Complex^{2,10} |
L | X,X^{10} |
X | X | L | 1/3FC | |||||||||

D-dimer Fragment^{2,10,11} |
L | X,X^{10} |
X | X | L | 1/3FC | |||||||||

Inflammation Factors: |
|||||||||||||||

Albumin^{1} |
X | X | X | X | |||||||||||

C-Reactive Protein^{2,10} |
X | X,X^{10} |
X | X | X | X | |||||||||

a_{1} -Acid glycoprotein^{2,10} |
L | X,X^{10} |
X | L | |||||||||||

anti-Twar antibodies^{3} |
X | ||||||||||||||

anti-CMV antibodies^{3} |
X | ||||||||||||||

anti-HSV-1 antibodies^{3} |
X | ||||||||||||||

White Cells^{1} |
X | X | X | X | |||||||||||

IGF-1^{23, 16,19} |
1/4FC | X | X^{z} |
X | |||||||||||

IL-6^{1} |
X^{9} |
Psaty | X^{31} |
X | X^{31} |
||||||||||

sCD14^{38} |
X | ||||||||||||||

ICAM-1^{11} |
X | 1/3FC | |||||||||||||

Serum anyloid P (SAP)^{14} |
X | ||||||||||||||

Pentracxin 3^{14} |
X | ||||||||||||||

Lp-PLA^{2, 12} |
X | X | |||||||||||||

TGF-Beta 1^{15} |
subset | 1/6FC | 1/2FC^{2}^{4} |
||||||||||||

antiphospholipid antibodies^{33} |
X C/C-3 | X C/C-3 | X C/C-3 | ||||||||||||

IGFBP1^{16} |
X^{z} |
X | |||||||||||||

IGFBP3^{16} |
X^{31} |
X^{31} |
X | ||||||||||||

Galectin-3^{37} |
X | X | X | blk | |||||||||||

Cytokines^{32} |
X | X | |||||||||||||

Oxidation Factors: |
|||||||||||||||

vit. E, B-carotene^{1} |
X | ||||||||||||||

Homocysteine/B_{6}^{20} |
1/5X | ||||||||||||||

myeloperoxidase^{22} |
subset | subset | |||||||||||||

Hormonal Factors: |
|||||||||||||||

Fasting Glucose^{1, 24} |
X | X | X | X^{24} |
X | X^{24} |
X | ||||||||

Fasting Insulin^{1} |
X | X | X | X^{24} |
|||||||||||

2-Hour OGTT^{1} |
X | X | |||||||||||||

2-Hour insulin | X | X^{24} |
|||||||||||||

HgA1c^{7} |
X | ||||||||||||||

TSH^{4} |
X | X^{26} |
X^{26} |
X^{26} |
X^{26} |
X^{26} |
|||||||||

FT4 | X^{4} Q |
X^{26} |
X^{26} |
X^{26} Q |
X^{26} Q |
X^{26} |
|||||||||

T3 | X^{26} |
X^{26} |
X^{26} |
X^{26} |
X^{26} |
||||||||||

TPO antibodies | X^{26} |
X^{26} |
X^{26} |
||||||||||||

C-Peptide^{24} |
X | ||||||||||||||

DHEA^{16, 19, 31, 25} |
subset^{19} |
X^{31} |
subset | subset | subset | X^{31} |
subset | X^{31} |
|||||||

Androstenedione^{16} |
1/5 FC^{25} |
X^{z} |
X | ||||||||||||

Testosterone^{25} |
1/5 FC | ||||||||||||||

SHBG^{25} |
1/5 FC | ||||||||||||||

Dihydrotestosterone^{25} |
1/5 FC | ||||||||||||||

PTH^{21} |
subset | subset | |||||||||||||

CML^{24} |
X | ||||||||||||||

b -Thromboglobulin^{1} |
P | ||||||||||||||

Platelet Count^{1} |
X | X | X | X | |||||||||||

Other: |
|||||||||||||||

Uric Acid^{1} |
X | X | X | ||||||||||||

Potassium^{1} |
X | X | X | ||||||||||||

Hgb/Hct^{1} |
X | X | X | X | |||||||||||

Klotho^{30} |
X | X | X | ||||||||||||

Medications: |
|||||||||||||||

Salicylate^{9} |
1/50FC | ||||||||||||||

Digoxin^{9} |
1/50FC | ||||||||||||||

Propranolol^{9} |
1/50FC | ||||||||||||||

Hydrochlorothiazide^{9} |
1/50FC | ||||||||||||||

Renal: |
|||||||||||||||

Cystatin C^{6, 16} |
X | X | X | X | X | ||||||||||

Urinary albumin^{7} |
X | X | |||||||||||||

Urinary creatinine^{7} |
X | X | |||||||||||||

Creatinine^{1, 16} |
X | X | X | X | X | ||||||||||

Serum Calcium^{21} |
subset | subset | |||||||||||||

Androstenedione^{16} |
|||||||||||||||

Serum Phosporus^{21} |
subset | subset | |||||||||||||

FGF-23^{29} |
X | ||||||||||||||

Alkaline Phosphatase^{21} |
X | X | |||||||||||||

Vitamins: |
|||||||||||||||

Vitamin D^{16, 21, 34} |
subset | subset | subset | X | |||||||||||

Bone: |
|||||||||||||||

BONAP (bone alkaline phos)^{21} |
subset | subset | |||||||||||||

Obesity-related: |
|||||||||||||||

Adiponectin total^{16, 18} |
X^{24} |
X^{24} |
X^{z} |
X | |||||||||||

Adiponectin HMW | X^{24} |
X^{24} |
|||||||||||||

Leptin^{18} |
subset | ||||||||||||||

Free Fatty Acid, NEFA | X^{24} |
X^{24} |
|||||||||||||

FABP4 | X^{24} |
X^{24} |
|||||||||||||

Fetuin A | X^{24} |
X^{24} |
|||||||||||||

Cardiac markers: |
|||||||||||||||

BNP^{17} |
X | X | X | X F/U | |||||||||||

ANP | subset | ||||||||||||||

Procollagen peptides^{8} |
subset | ||||||||||||||

Troponin^{27} |
X | X | X | blk | |||||||||||

ST2^{37} |
X | X | X | blk | |||||||||||

Gas6^{28} |
1/4 C/C | 1/4 C/C |

Full or FC |
Full CHS cohort |

C/C |
a Case/Control study with about 400 people unless noted otherwise |

X-Sec |
a cross-sectional study with 400 people |

C/C-2 |
the second Case/Control group, which has 2000 members for phenotypes and 2500 for genotypes |

Black |
Extra Black cohort |

X |
done or in process of being done |

L |
part of a longitudinal study (n= ~1500 people) |

1/2FC |
fractions of the CHS full cohort used in the study; for example 1/2FC = ~2500 people |

P |
Planned; for some, $ in hand; for others, funding being sought |

z |
Only those with data in year 18 |

Q |
Measured only in participants with abnormal TSH |

M |
Measured only in male participants free of CVD |

C/C-3 |
a case/control study |

MS |
Sample from Cognition study |

^{1}Funds from CHS (AS#12IP) |

^{2}Funds from R.Tracy RO1 (AS#8) |

^{3}Funds from D.Siscovic grant (AS#13) |

^{4}Funds from L.Fried grant (AS#12) |

^{5}Funds from Kurosawa (AS#168) |

^{6}Funds from Sarnak (AS#164) |

^{7}Funds from Konen (AS#6) |

^{8}Funds from Barasch (AS#122) |

^{9}Funds from Psaty Grant (AS#10C) |

^{10}Funds from Cushman grant (AS#27) |

^{11}Funds from Steve Humphries (AS#8) |

^{12}Funds from Furberg (AS#149) |

^{13}Funds from Koschinsky(AS#83) |

^{14}Funds from Jenny grant (AS#128) |

^{15}Funds from Glazer-Siscovick (AS#166) |

^{16}Funds from Linda Fried (AS#142) |

^{17}Funds from De Fillippi ancillary study (AS#179) |

^{18}Funds from Kizer grant (AS#147) |

^{19}Funds from Cappila grant (AS#163) |

^{20}Funds from Schwartz (AS#24,25) |

^{21}Funds from Kestenbaum(AS#160) |

^{22}Funds from Aviles(AS#88) |

^{23}Funds from Kaplan(AS#88) |

^{24}Funds from Mukamal(AS#216) |

^{25}Funds from Shores(AS#200) |

^{26}Funds from Cappola(AS#207) |

^{27}Funds from De Fillippi (AS#241) |

^{28}Funds from Borgel(AS#182) |

^{29}Funds from Ix(AS#251) |

^{30}Funds from Samba (AS#270) |

^{31}Funds from Newman (AS#127) |

^{32}Funds form Walston (AS#167) |

^{33}Funds from Kittner (AS#55) |

^{34}Funds from Kestenbaum (AS#260) |

^{35}Funds from Folsom (AS#198) |

^{36}Funds from Kuller (AS#110) |

^{37}Funds from De Fillippi (AS#284) |

^{38} Funds from Reiner (AS#87) |

modified 12/15/2015